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SARAbstract As a part of our ongoing studies in developing new derivatives as antimicrobial agents we
describe the synthesis of novel substituted 5-benzylideno-2-adamantylthiazol[3,2-b][1,2,4]triazol-6
(5H)ones.The twenty-five newly synthesized compounds were tested for their antimicrobial and
antifungal activity. All compounds have shown antibacterial properties with compounds 1–9 show-
ing the lowest activity, followed by compounds 10–14 while compounds 15–25 the highest antibac-
terial activity. Specific compounds appeared to be more active than ampicillin in most studied
strains and in some cases more active than streptomycin. Antifungal activity in most cases also
was better than that of reference drugs ketoconazole and bifonazole. Elucidating the relation of1,2,4]tri-
2 C. Tratrat et al.
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azol-6(5H)ones. Pharmacophore models formolecular properties to antimicrobial activity as well as generation of pharmacophore model for
antifungal activity of two fungal species Aspergillus fumigatus and Candida albicans were performed.
 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
During the past 50 years the significant efforts in the diagnosis and
treatment of microbial diseases (Fernandes, 2006) led to impressive
gains in the treatment of microbial diseases introducing a range of
therapeutic strategies in clinical practice. However, in spite of a large
number of antibiotics and chemotherapeutics available for medical
use there is still an urgent medical need for new classes of antibacterial
agents, due to the emergence of old and new antibiotics’ resistance
created in the last decades. A potential approach that addresses this
issue of resistance is the design of novel agents with different mode
of action in order to avoid the occurrence of cross resistance with
the present therapeutics.
Five member heterocycles with two of three heteroatoms, such as
imidazoles, thiazoles, triazoles and others are key structural units in
many pharmaceutical preparations.
Specifically, 1,2,4-triazoles and their heterocyclic derivatives repre-
sent an interesting class of compounds possessing a wide spectrum of
biological activities. A large number of 1,2,4,-triazole derivatives con-
taining ring systems exhibit antibacterial (Gabriela et al., 2010;
Upmanyu et al., 2011; Prasad et al., 2012; Taj et al., 2013; Kumar
et al., 2014; Gupta et al., 2015), antifungal (Sangshetti et al., 2009;
Zoumpoulakis et al., 2012; Barbuceanu et al., 2009, 2012; Sahu
et al., 2014; Gupta et al., 2015) antitubercular (Gill et al., 2008;
Kumar et al., 2010; Cristophe et al., 2011; Godhani et al., 2015), anal-
gesic (Amir et al., 2008;Tozkoparan et al., 2012; Khanage et al., 2013;
Sarigol et al., 2015), anti-inflammatory (Pattan et al., 2012; Ayse et al.,
2012; Ashour et al., 2013; Sarigol et al., 2015), anticancer (Romagnoli
et al., 2010; Wang et al., 2011; Bai et al., 2012), anticonvulsant
(Siddiqui et al., 2010; Dayanand et al., 2011; Botros et al., 2013;
Plech et al., 2013; Kamboj et al., 2015), antiviral (Abdel-Aal et al.,
2008; Jordao et al., 2009; El-Etrawy et al., 2010), antimalarial
(Mishra et al., 2008; Gujjar et al., 2009) central nervous system
(Kamboj et al., 2015) and other activities (Puthiyapurayil et al.,
2012; Iqbal et al., 2012).
Additionally, the thiazolyl group bears great importance in biolog-
ical systems. In this context, thiazole derivatives find a variety of appli-
cations such as bacteriostatics (Abdel-Wahab et al., 2009; Dawane
et al., 2010; Kouatly et al., 2010; Zablotskaya et al., 2013; Haroun
et al., 2016), antibiotics (Mostafa and Abd El-Salam, 2013), antifungal
(Bharti et al., 2010), CNS regulants of high selling diuretics (Sucman
et al., 2011), local anaesthetics (Geronikaki et al., 2009), anti-
inflammatory (Lagunin et al., 2008; Kouatly et al., 2009; Pattan
et al., 2009; Apostolidis et al., 2013), analgesic and antipyretics
(Pattan et al., 2009; Saravanan et al., 2011), HIV infections (Pitta
et al., 2010, 2013), antiallergic (Hargrave et al., 1983), antihyperten-
sives (Abdel-Wagab et al., 2008), against schizophrenia (Gupta,
2013), antidiabetic (Lino et al., 2009), anthelminthic (Amnerkar and
Bhusari, 2011), anticancer (Luzina and Popov, 2009; Liu et al., 2009)
and antioxidant (Gouda et al., Geronikaki et al., 2013). Furthermore,
the thiazole ring is also found in many potent biologically active mole-
cules. In particular, Thiabendazole and 2-(p-chlorophenyl) thiazole-4-
acetic acid are widely used as anti-inflammatory drugs (van Arman and
Campbell, 1975). Meloxicam is a new NSAID with a thiazolyl group in
its structure (Kumar and Mishra, 2006). Some other thiazole deriva-
tives are antiulcer (Nizatidine), antiretroviral (Ritonavir) (De Souza
and De Almeida, 2003) agents, while others (Van Arman and
Campbell, 1975; Ramachandran et al., 2011; Vicini et al., 2008) as well
as Niridazole (Kilpatrick et al., 1982) have been found to exhibit
antimicrobial antifungal/antihelminthic activities.et al., Design, synthesis and biological
antifungal activity. Arabian Journal ofAnother interesting core in medicinal chemistry responsible for
numerous pharmacological properties and biological activities is the
thiazolidinone (Knutsen et al., 2007; Apostolidis et al., 2013). Many
publications refer to antifungal activity of different thiazole and thia-
zolidinone derivatives (Amnerkar and Bhusari, 2011; Apostolidis
et al., 2013; Marques et al. 2014; Gupta et al., 2016; Haroun et al.,
2016).
In view of these facts the thiazolo[3,2-b]1,2,4-triazoles are com-
pounds with broad spectrum of biological activities, such as antimicro-
bial (Barbuceanou et al., 2009; Karthikeyan, 2009; Gupta et al., 2015),
anticancer (Lesyk et al., 2007; Kaminskyy et al., 2011), anti-
inflammatory (Tozkoparan et al., 2000; Dog˘das et al., 2007;
Apostolidis et al., 2013) and analgesic (Αssarzadeh, 2014) as well as
antihypertensive (Bhandari et al., 2009) and anti-diabetic (Calderone
et al., 2009).
Moreover, adamantane derivatives have been documented for their
antiviral activity against influenza A (McSharry et al., 2007; Galva˜o
et al., 2014) and HIV viruses (Balzarini et al., 2009; Pitta et al.,
2010). Several adamantane derivatives were also associated with cen-
tral nervous system (Suh et al., 2005), antimicrobial (Kadi et al.,
2007) and anti-inflammatory activities (Kadi et al., 2007;
Tozkoparan et al., 2012; Karthikeyan, 2008; Kouatly et al., 2009).
These findings focused particular interest on the incorporation of
thiazolo[3,2-b]1,2,4-triazole with adamantine ring in one frame in
order to obtain compounds with improved/higher antibacterial and
antifungal activities.
To this extend, twenty-five new 5-arylidene -2-adamatylthiazol[3,3-
b]triazol-6(5H)-ones (Scheme 1,1–25) were synthesized and evaluated
for their in vitro antimicrobial properties against Gram positive, Gram
negative bacteria and fungi strains. To a step further, multivariate data
analysis highlighted the relation between molecular properties to
antimicrobial and antifungal activities of the synthesized compounds.
2. Results and discussion
2.1. Chemistry
Τhe synthesis of title compounds was performed by a multistep
reaction as shown in Scheme 1. Adamantane thiosemicarbizide
(3) was synthesized using a procedure reported earlier starting
from adamantine-1-carbonyl chloride (1) upon reaction with
thiosemicarbazide (2), followed by cyclization in alkaline solu-
tion under reflux to 5-adamantyl-4H-1,2,4-trizol-3-thiole (3).
The third step includes the one pot condensation of 5-adaman
tyl-4H-1,2,4-triazol-3-thiole (4) with bromoacetic acid and
appropriate substituted benzaldehydes in the presence of
sodium acetate and acetic anhydride (Karthikeyan et al.,
2008). Reactions proceed smoothly with good yields (55–88%).
All new structures of compounds 1–25 were characterized
by IR, 1H NMR and elemental analysis. IR spectra showed
absorptions at 1724–1747 cm1 (C‚O) and at 1578–
1654 cm1 (C‚N). In the 1H NMR spectra the title com-
pounds showed peaks in the region of 1.75–2.36 ppm
(adamantine), 7.12–7.80 ppm (ArAH) and 8.11–8.48 ppm
(CH‚).
During the reaction of 5-adamantyl-4H-1,2,4-trizol-3-thiole
with different dielectrophiles the formation of two cyclicevaluation of new substituted 5-benzylideno-2-adamantylthiazol[3,2-b][1,2,4]tri-
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Scheme 1 Synthesis of 5-benzylideno-2-adamantyltheiazol[3,2-b][1,2,4]triazol-6(5H)ones.
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Scheme 2 Formation of thiazolo[3,2-b]-1,2,4-triazole.
Pharmacophore models for antifungal activity 3isomers, (a) thiazolo[3,2-b]-1,2,4-triazole and (b) thiazolo[3,2-
c]-1,2,4-triazole is possible (Karthikeyan, 2008) (Scheme 2).
Compounds 1–25 exist as potential E and Z geometrical
isomers; the Z conformation of the 5 exocyclic C‚C double
bond was assigned on the basis of literature data for analogues
structures (Ottana` et al., 2005) as well as on experimental data
(1H NMR) by comparing the resonance region of the hydro-
gens of the 5-adamantyl-4H-1,2,4-triazole-3-thiole to the cor-
responding ones of the final compounds (Scheme 2). The
adamantane protons of thiol group resonated at 1.70–
2.51 ppm, while the adamantane protons of the title com-
pounds resonated at 1.75–2.36 ppm. It is obvious that both
the title and intermediate compounds showed peaks for
adamantane hydrogens in the same area, confirming the for-
mation of the Z isomer thiazolo[3,2-b]-1,2,4-triazole. On the
contrary, in case of the formation of E isomer, the aromatic
ring protons will appear at higher chemical shift values,
deshielded by the adjacent C‚O.
2.2. Antimicrobial activity
The results of antibacterial activity of the compounds 1–25 are
presented in Table 1. Almost all the tested compounds showedPlease cite this article in press as: Tratrat, C. et al., Design, synthesis and biological
azol-6(5H)ones. Pharmacophore models for antifungal activity. Arabian Journal ofantibacterial activity but on different level. Compounds 15–25
showed higher antibacterial potential than others with MIC
ranged between 4.5–26.4 * 10
2 lmol/mL and MBC 9.0–
42.2 * 10
2 lmol/mL. The majority of the compounds were
inactive against Micrococcus flavus. Compound 15, did not
show activity at tested concentration againstM. flavus, Staphy-
lococcus aureus, Pseudomonas aeruginosa, Salmonella typhi-
murium and E. faecalis, 19 and 25 on P. aerugunisa and
E. faecalis, 22 on Bacillus cereus, Escherichia coli and E. fae-
calis, while 21 on E. coli and E. faecalis. The antibacterial
potential of tested compounds could be presented as follows:
18 > 24 > 23 > 17 > 16 > 19 > 20 > 25 > 21 > 22 > 15.
It can be seen that compound 18 showed the best antibacterial
activity with MIC in the interval 4.90–9.80 * 10
2 lmol/mL
and MBC 9.80–36.6 * 10
2 lmol/mL. This compound is fol-
lowed by 24 with MIC at 4.5–13.6 * 10
2 lmol/mL and
MBC between 9.0–27.1 * 10
2 lmol/mL. The lowest antibacte-
rial activity among all tested compounds was obtained for
compound 15 with inhibitory activity at 5.3–26.4 * 10
2
lmol/mL and bactericidal effect at .10.5- > 42.2 * 10
2
lmol/mL. Ampicillin showed inhibitory effect at 24.8–
74.4 * 10
2 lmol/mL and bactericidal at 37.2–124.0 * 10
2
lmol/mL, while Streptomycin showed MIC in range ofevaluation of new substituted 5-benzylideno-2-adamantylthiazol[3,2-b][1,2,4]tri-
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Table 1 Antibacterial activity of XK compounds (MIC and MBC, lmo/ml  102).
Compounds S.a. B.c. M. f L. m. Ps. aer. S. typhi E. coli En.faec En.cl
1 MIC 225 ± 1.7g 550 ± 1.7h – 110 ± 3.3j 220 ± 1.7d 220 ± 0.7c – 330 ± 1.0f –
MBC 550 ± 1.7h 550 ± 2.7g – 440 ± 1.7f 660 ± 1.0g 550 ± 1.7g – 660 ± 1.7h –
2 MIC 177 ± 1.8f 252 ± 0.6d – 101 ± 0.2ef 705 ± 0.3k 252 ± 0.6f – 378 ± 0.2h –
MBC 604 ± 1.3i 504 ± 1.1e – 214 ± 0.1e 806 ± 0.5h 503 ± 0.2f – 504 ± 0.1f –
3 MIC 176 ± 0.6f 554 ± 1.2h – 101 ± 0.3f 504 ± 0.2g 252 ± 0.6f – 252 ± 0.1e –
MBC 504 ± 1.1f 604 ± 1.4h – 504 ± 0.2i 604 ± 0.1f 504 ± 0.5f – 504 ± 1.1f –
4 MIC 98 ± 1.7c 25 ± 0.2b – 98 ± 0.9d 343 ± 0.2e 245 ± 1.0e – 245 ± 1.7d –
MBC 490 ± 1.7e 490 ± 3.3d – 490 ± 6.6g 490 ± 1.5c 490 ± 1.7e – 490 ± 1.7d –
5 MIC 345 ± 1.6h 394 ± 0.6e – 345 ± 0.8i 542 ± 1.5h 394 ± 0.07g – 492 ± 0.2i –
MBC 492 ± 0.9e 492 ± 1.3d – 492 ± 1.2h 591 ± 2.9e 492 ± 0.1e 492 ± 1.3c 492 ± 0.1e –
6 MIC 101 ± 0.4d 253 ± 0.5d 607 ± 2.4c 253 ± 1.7h 455 ± 0.6f 455 ± 0.3i – 354 ± 1.4g –
MBC 607 ± 0.2j 506 ± 2.0e – 506 ± 1.0i 607 ± 0.7f 506 ± 1.0f – 506 ± 2.0f –
7 MIC 356 ± 1.8i 488 ± 2.5f – 98 ± 0.5de 683 ± 1.6j 244 ± 0.2d – 244 ± 1.3d –
MBC 488 ± 2.5d 537 ± 2.1f – 488 ± 0.9gh – 488 ± 1.0d – 488 ± 0.3d –
8 MIC 94 ± 0.6c 165 ± 0.3c – 94 ± 0.1d 140 ± 1.7c 24 ± 0.2b – 112 ± 1.1c –
MBC 140 ± 1.7c 140 ± 1.7c – 165 ± 0.07d 566 ± 0.7d 140 ± 0.7c – 140 ± 0.7c –
9 MIC 154 ± 0.7e 528 ± 2.7g – 88 ± 0.7c 616 ± 2.0i 440 ± 0.07h – 528 ± 2.7j –
MBC 528 ± 2.7g 616 ± 2.4i – 154 ± 0.7c – 616 ± 2.0h – 616 ± 2.0g –
10 MIC 24 ± 0.1cd 24 ± 0.1c 49 ± 0.3c 49 ± 0.3d 122 ± 0.3e 122 ± 0.6e 73 ± 0.07b 122 ± 0.7e –
MBC 151 ± 0.1e 98 ± 0.2d 195 ± 0.07de 171 ± 0.3e 146 ± 0.1d 146 ± 0.1e 195 ± 0.4d 146 ± 0.4d –
11 MIC 25 ± 0.0d 25 ± 0.2c 49 ± 0.2d 49 ± 0.3d 98 ± 0.7d 98 ± 0.3d 98 ± 0.2e 98 ± 0.7d –
MBC 147 ± 2.3d 98 ± 0.3d 147 ± 0.7b 172 ± 0.2f 172 ± 0.2e 172 ± 0.2f 196 ± 0.7e 172 ± 0.6e –
12 MIC 163 ± 0.07f 151 ± 0.2f 163 ± 0.07f 126 ± 0.03f 378 ± 0.2f 378 ± 0.3f 226 ± 0.3f 226 ± 0.6f –
MBC 201 ± 0.3g 201 ± 0.3e 201 ± 0.3e 226 ± 0.3g 504 ± 0.2f 504 ± 0.2g 504 ± 0.2f 504 ± 0.1f –
13 MIC 19 ± 0.2b 23 ± 0.07b 93 ± 0.3e 58 ± 0.7e 23 ± 0.07b 46 ± 0.1c 93 ± 0.3d 23 ± 0.6bc –
MBC 46 ± 0.1c 46 ± 0.1c 186 ± 0.3c 93 ± 0.3d 46 ± 0.1b 56 ± 0.2c 186 ± 0.2c 46 ± 0.5b –
14 MIC 93 ± 0.3e 46 ± 0.1e 93 ± 0.07e 46 ± 0.1c 23 ± 0.1b 46 ± 0.1c 93 ± 0.07d 23 ± 0.3b –
MBC 186 ± 0.2f 58 ± 0.1c 186 ± 1.2cd 70 ± 0.2b 46 ± 0.5b 70 ± 0.2d 186 ± 0.2c 46 ± 0.5b –
15 MIC 13.2 ± 0.07ef 26 ± 0.1g 11 ± 0.2c 5 ± 0.1b 16 ± 0.3f 16 ± 0.07e 11 ± 0.2de – 13 ± 0.07d
MBC 42 ± 0.07j 32 ± 0.2e 42 ± 0.07h 11 ± 0.2bc 42 ± 0.1h 42 ± 0.07j 21 ± 0.4f – 21 ± 0.03c
16 MIC 11 ± 0.2c 26 ± 0.5g 11 ± 0.2c 5 ± 0.03b 16 ± 0.3f 16 ± 0.07e 11 ± 0.2e – 13 ± 0.09d
MBC 26 ± 0.1e 32 ± 0.2e 21 ± 0.4b 11 ± 0.2c 26 ± 0.1b 26 ± 0.1g 21 ± 0.4f – 19 ± 0.2b
17 MIC 13 ± 0.1e 15 ± 0.07d 5 ± 0.09a 5 ± 0.03b 10 ± 0.07b 10 ± 0.07c 10 ± 0.07d – 13 ± 0.2c
MBC 31 ± 0.2g 31 ± 0.2e 41 ± 0.2f 10 ± 0.07b 18 ± 0.3a 13 ± 0.2b 18 ± 0.1d – 18 ± 0.3b
18 MIC 5 ± 0.1b 5 ± 0.03a 5 ± 0.1a 10 ± 0.3d 9 ± 0.1a 10 ± 0.3b 7 ± 0.1b – 9 ± 0.1a
MBC 15 ± 0.2b 10 ± 0.1a 15 ± 0.2a 24 ± 0.1e 37 ± 0.2f 24 ± 0.1g 15 ± 0.2b – 37 ± 0.2e
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Table 1 (continued)
Compounds S.a. B.c. M. f L. m. Ps. aer. S. typhi E. coli En.faec En.cl
19 MIC 11 ± 0.1d 14 ± 0.2c 9 ± 0.09b 7 ± 0.09a 11 ± 0.1c 16 ± 0.3e 9 ± 0.03ab – 11 ± 0.1b
MBC 18 ± 0.07c 16 ± 0.3b 37 ± 0.2d 9 ± 0.2c 37 ± 0.2f 23 ± 0.3e 16 ± 0.3c – 16 ± 0.05a
20 MIC 12 ± 0.2d 14 ± 0.3c 9 ± 0.1b 7 ± 0.1a 23 ± 0.03h 19 ± 0.2f 9 ± 0.1c – 12 ± 0.2b
MBC 19 ± 0.2c 28 ± 0.2d 37 ± 0.3e 9 ± 0.2e 28 ± 0.2c 23 ± 0.03f 19 ± 0.2e – 19 ± 0.2b
21 MIC 13 ± 0.03ef 16 ± 0.7d 11 ± 0.2c 11 ± 0.2e 16 ± 0.2f 16 ± 0.2e 11 ± 0.2de – 13 ± 0.03d
MBC 31 ± 0.2h 31 ± 0.2e 42 ± 0.03gh 16 ± 0.2d 3 ± 0.1d 19 ± 0.1d 42 ± 0.3h – 21 ± 0.3c
22 MIC 13 ± 0.1f 21 ± 0.2e 16 ± 0.2f 5 ± 0.07b 16 ± 0.1f 16 ± 0.1e 11 ± 0.07de – 16 ± 0.3e
MBC 31 ± 0.1h 42 ± 0.1g 42 ± 0.6g 11 ± 0.2bc 31 ± 0.1d 31 ± 0.2h 42 ± 0.03h – 18 ± 0.1b
23 MIC 11 ± 0.1d 14 ± 0.2c 9 ± 0.1b 5 ± 0.2a 14 ± 0.2e 14 ± 0.2d 9 ± 0.2c – 11 ± 0.1b
MBC 27 ± 0.3f 27 ± 2.7d 36 ± 0.0d 9 ± 0.2a 27 ± 0.03c 16 ± 0.3c 18 ± 0.1de – 16 ± 0.3a
24 MIC 11 ± 0.1d 23 ± 0.3e 14 ± 0.2e 5 ± 0.3a 14 ± 0.2e 14 ± 0.07d 7 ± 0.1a – 9 ± 0.1a
MBC 23 ± 0.2d 27 ± 0.1d 36 ± 0.07d 9 ± 0.1a 27 ± 0.3c 23 ± 0.2e 9 ± 0.07a – 16 ± 0.3a
25 MIC 11 ± 0.1d 16 ± 0.3d 11 ± 0.1d 7 ± 0.3c 14 ± 0.3d 14 ± 0.1d 9 ± 0.7c – 14 ± 0.2d
MBC 23 ± 0.2d 23 ± 0.2c 36 ± 0.4d 9 ± 0.2a 36 ± 0.07g 23 ± 0.2e 18 ± 0.03de – 18 ± 0.03b
Ampi–cilin MIC 25 ± 0.3bcg 25 ± 0.2bdf 25 ± 0.0bbh 37 ± 0.07bbg 37 ± 0.07bci 25 ± 0.2bbg 74 ± 0.07bcg 25 ± 0.3bc 74 ± 0.3g
MBC 37 ± 0.07bbi 37 ± 0.07bbf 38 ± 0.02aae 74 ± 0.1bcg 49 ± 0.07bci 38 ± 0.07bbi 124 ± 0.6bbi 49 ± 0.07bc 124 ± 0.7f
Strepto–mycin MIC 4 ± 0.1aaa 9 ± 0.2aab 17 ± 0.02aag 26 ± 0.3aaf 17 ± 0.07acg 4 ± 0.0aaa 27 ± 0.1aaf 17 ± 0.07aa 27 ± 0.3d
MBC 8 ± 0.1aaa 17 ± 0.07aab 34 ± 0.1aac 52 ± 0.2aaf 34 ± 0.1ace 9 ± 0.1aaa 34 ± 0.7aag 34 ± 0.1aa 34 ± 0.3f
In each line different letters mean significant differences between the compounds (p < 0.05).
a–j – letters mean significant differences between the compounds in group 1–9.
a–g – letters mean significant differences between the compounds in group 10–14.
A–j – letters mean significant differences between the compounds in group 15–25.
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Table 2 Antifungal activity of XK compounds (MIC and MFC, lmo/ml  102).
Compounds A.fum. A.v. A.o. A.n. T.v. P.f. P.o. C.a.
1 MIC 28 ± 0.2d 28 ± 0.2c 55 ± 0.3h 28 ± 0.2b 28 ± 0.2d 28 ± 0.2d 7 ± 0.3a –
MFC 165 ± 0.3g 55 ± 0.3c 110 ± 3.3f 165 ± 0.7f 138 ± 0.2h 55 ± 0.3b 28 ± 0.2a –
2 MIC 25 ± 0.03c 6 ± 0.03a 25 ± 0.03d 75 ± 0.1h 25 ± 0.03c 6 ± 0.09a 25 ± 0.03b 200 ± 0.6f
MFC 100 ± 0.1e 25 ± 0.03a 50 ± 0.07b 100 ± 0.5e 100 ± 0.2ef 25 ± 0.3a 50 ± 0.07b –
3 MIC 25 ± 0.03e 126 ± 0.2g 25 ± 0.03d 75 ± 0.3h 25 ± 0.03bc 6 ± 0.1a 25 ± 0.03b –
MFC 75 ± 0.07b 151 ± 0.2g 50 ± 0.3b 100 ± 0.1e 100 ± 0.3ef 25 ± 0.0a 50 ± 0.07b –
4 MIC 25 ± 0.2b 25 ± 0.2b 25 ± 0.2c 74 ± 0.2g 25 ± 0.2bc 6 ± 0.04a 25 ± 0.2b 25 ± 0.03b
MFC 98 ± 0.3d 49 ± 0.3b 49 ± 0.3b 172 ± 0.2g 98 ± 0.3e 25 ± 0.2a 49 ± 0.3b 123 ± 0.6d
5 MIC 25 ± 0.2bc 25 ± 0.2b 6 ± 0.06a 25 ± 0.2a 25 ± 0.1bc 6 ± 0.05a 25 ± 0.2b –
MFC 98 ± 0.1d 49 ± 0.07b 25 ± 0.3a 98 ± 0.1d 74 ± 0.6b 25 ± 0.2a 49 ± 0.07b –
6 MIC 76 ± 0.3h 76 ± 0.3e 76 ± 0.3j 76 ± 0.3i 76 ± 0.3g 6 ± 0.1a 6 ± 0.1a 25 ± 0.03b
MFC 177 ± 0.3i 127 ± 0.2f 177 ± 0.3h 101 ± 0.07e 101 ± 0.3f 76 ± 0.3e 76 ± 0.3e 51 ± 0.06b
7 MIC 24 ± 0.1b 6 ± 0.03d 24 ± 0.1c 73 ± 0.07g 24 ± 0.1b 24 ± 0.1c 49 ± 0.3c 24 ± 0.03a
MFC 171 ± 0.07h 24 ± 0.1a 49 ± 0.3b 171 ± 0.3g 49 ± 0.3a 73 ± 0.07d 98 ± 0.2g
8 MIC 24 ± 0.2a 6 ± 0.03a 24 ± 0.2b 71 ± 0.3f 24 ± 0.2a 24 ± 0.2b 24 ± 0.2b 24 ± 0.1a
MFC 94 ± 0.1c 24 ± 0.2a 165 ± 0.07g 94 ± 0.1c 118 ± 0.7g 71 ± 0.07c 71 ± 0.3d –
9 MIC 66 ± 0.3g 66 ± 0.2e 66 ± 0.3i 66 ± 0.3e 66 ± 0.0f 66 ± 0.3g 66 ± 0.3d 176 ± 0.6e
MFC 154 ± 0.7f 88 ± 0.3e 88 ± 0.3d 88 ± 0.3b 88 ± 0.3d 88 ± 0.3g 88 ± 0.0f –
10 MIC 12 ± 0.07a 6 ± 0.03a 24 ± 0.1b 73 ± 0.3f 12 ± 0.07a 6 ± 0.09ab 24 ± 0.1b 171 ± 0.3b
MFC 98 ± 0.2d 24 ± 0.1b 49 ± 0.4b 98 ± 0.2c 49 ± 0.3a 24 ± 0.1b 98 ± 0.2e –
11 MIC 25 ± 0.2b 25 ± 0.2b 25 ± 0.2b 25 ± 0.2a 25 ± 0.2c 25 ± 0.2c 25 ± 0.2b –
MFC 147 ± 0.3f 98 ± 0.3d 147 ± 0.3f 98 ± 0.3c 74 ± 0.2b 49 ± 0.3c 74 ± 0.5d –
12 MIC 51 ± 0.3f 6 ± 0.1a 25 ± 0.03c 75 ± 0.1g 51 ± 0.3e 6 ± 0.1b 25 ± 0.4b 176 ± 0.6c
MFC 100 ± 0.2e 25 ± 0.4b 51 ± 0.3c 176 ± 0.2f 100.±0.3e 51 ± 0.3d 51 ± 0.07b –
13 MIC 46 ± 0.1d 6 ± 0.3a 6 ± 0.07a 70 ± 0.2d 46 ± 0.1d 6 ± 0.07a 23 ± 0.07a –
MFC 93 ± 0.07b 23 ± 0.07a 46 ± 0.1a 162 ± 0.1e 93 ± 0.07d 23 ± 0.4a 46 ± 0.1a –
14 MIC 46 ± 0.5a 6 ± 0.2a 6 ± 0.1a 70 ± 0.03e 23 ± 0.4b 6 ± 0.1a 23 ± 0.4a –
MFC 93 ± 0.07b 23 ± 0.3a 46 ± 0.5a 139 ± 0.6d 93 ± 0.3d 23 ± 0.07a 46 ± 0.1a –
15 MIC 13 ± 0.06c 13 ± 0.07d 13 ± 0.06d 13 ± 0.06cd 13 ± 0.06e 13 ± 0.06c 13 ± 0.07d 21 ± 0.4d
MFC 26 ± 0.1g 26 ± 0.1g 26 ± 0.1f 39 ± 0.2i 21 ± 0.3d 26 ± 0.1d 26 ± 0.1e 40 ± 0.3i
16 MIC 13 ± 0.4c 13 ± 0.4cd 13 ± 0.4cd 13 ± 0.1cd 13 ± 0.06e 13 ± 0.4c 13 ± 0.1d 21 ± 0.3e
MFC 37 ± 0.3j 26 ± 0.5g 26 ± 0.1f 37 ± 0.3h 16 ± 0.3c 26 ± 0.5d 26 ± 0.5e 37 ± 0.3h
17 MIC 12 ± 0.2c 13 ± 0.2c 13 ± 0.2c 13 ± 0.1c 13 ± 0.2d 13 ± 0.1c 13 ± 0.2c 20 ± 0.1d
MFC 36 ± 0.2i 25 ± 0.1f 13 ± 0.2c 25 ± 0.1c 25 ± 0.1f 20 ± 0.1b 25 ± 0.1d 36 ± 0.2g
18 MIC 5 ± 0.2a 5 ± 0.2a 5 ± 0.3a 4 ± 0.2a 5 ± 0.03a 5 ± 0.3a 5 ± 0.03a 10 ± 0.3a
MFC 10 ± 0.3a 10 ± 0.3a 7 ± 0.2a 11 ± 0.07a 7 ± 0.1a 10 ± 0.6a 7 ± 0.1a 20 ± 0.2a
19 MIC 11 ± 0.3b 11 ± 0.2b 11 ± 0.1b 11 ± 0.1b 11 ± 0.1b 23 ± 0.3d 11 ± 0.1b 23 ± 0.3f
MFC 18 ± 0.07d 23 ± 0.3de 18 ± 0.06e 32 ± 0.3d 23 ± 0.3e 32 ± 0.3e 23 ± 0.3bc 32 ± 0.2d
20 MIC 12 ± 0.2b 12 ± 0.1b 12 ± 0.2b 23 ± 0.03e 12 ± 0.2b 23 ± 0.03d 12 ± 0.07b 23 ± 0.1g
MFC 14 ± 0.3b 23 ± 0.03e 14 ± 0.03d 32 ± 0.1e 14 ± 0.3b 32 ± 0.1ef 23 ± 0.03c 32 ± 0.1e
21 MIC 13 ± 0.4c 13 ± 0.2d 13 ± 0.4cd 13 ± 0.1d 13 ± 0.4de 13 ± 0.03c 13 ± 0.2d 16 ± 0.2c
MFC 16 ± 0.2c 37 ± 0.2i 26 ± 0.07f 37 ± 0.2h 37 ± 0.2j 26 ± 0.07d 26 ± 0.07e 26 ± 0.07c
22 MIC 13 ± 0.03c 13 ± 0.03d 13 ± 0.03d 13 ± 0.2d 13 ± 0.03e 13 ± 0.4c 13 ± 0.2d –
MFC 21 ± 0.3e 16 ± 0.2c 33 ± 0.4g 33 ± 0.03f 33 ± 0.07h 33 ± 0.03f 33 ± 0.2f –
23 MIC 11 ± 0.1b 11 ± 0.1b 11 ± 0.1b 11 ± 0.1b 23 ± 0.2f 11 ± 0.1b 11 ± 0.1b 23 ± 0.2f
MFC 23 ± 0.2f 23 ± 0.2d 14 ± 0.2d 37 ± 0.2h 32 ± 0.2g 23 ± 0.2c 23 ± 0.2b 32 ± 0.2d
24 MIC 11 ± 0.1b 11 ± 0.07b 11 ± 0.1b 11 ± 0.1b 22 ± 0.2f 11 ± 0.2b 11 ± 0.07b 11 ± 0.1b
MFC 23 ± 0.2f 11 ± 0.1b 11 ± 0.1b 23 ± 0.2b 32 ± 0.2g 23 ± 0.5c 23 ± 0.1b 23 ± 0.2b
25 MIC 11 ± 0.2b 11 ± 0.1b 11 ± 0.2b 11 ± 0.1b 11 ± 0.1b 11 ± 0.1b 11 ± 0.1b 32 ± 0.2h
MFC 32 ± 0.2h 35 ± 0.2h 18 ± 0.4e 35 ± 0.2g 35 ± 0.2i 35 ± 0.2g 35 ± 0.2g 35 ± 0.2f
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Table 2 (continued)
Compounds A.fum. A.v. A.o. A.n. T.v. P.f. P.o. C.a.
Ketoconazole MIC 38.0 ± 0.3ecd 285 ± 0.3hdf 38 ± 0.3fde 38 ± 0.3cbf 475 ± 0.7hfh 38 ± 0.3ede 380 ± 3.3ecf 38 ± 0.03dai
MFC 95.0 ± 0.0ccl 380 ± 2.0hek 95 ± 0.3eei 95 ± 0.3cbk 570 ± 3.3ifl 95 ± 0.0hei 380 ± 3.0hfi 94 ± 0.6ck
Bifonazole MIC 48.0 ± 0.3eee 48 ± 0.0dce 48 ± 0.3gef 48 ± 0.3dcg 64 ± 0.3egg 64 ± 0.3fef 48 ± 0.3cde 32 ± 0.0cah
MFC 64.0 ± 0.3aak 64 ± 0.3dcj 80 ± 0.7cdh 64 ± 0.0aaj 80 ± 0.3cck 80 ± 0.3feh 64 ± 0.3cch 48 ± 0.6aj
In each line different letters mean significant differences between the compounds (p< 0.05).
a–j – letters mean significant differences between the compounds in group 1–9.
a–g – letters mean significant differences between the compounds in group 10–14.
a–j – letters mean significant differences between the compounds in group 15–25.
Pharmacophore models for antifungal activity 74.3–25.8  102 lmol/mL and MBC of 8.6–51.6  102 lmol/
mL. It can be seen that all the compounds tested for antibac-
terial activity showed better effect than the commercial antibi-
otic ampicillin with exception of those compounds that did not
show any activity in tested concentrations. On the other hand,
all the compounds tested exhibited even better antibacterial
activity than Streptomycin against Listeria monocytogenes
and E. coli (except for 22 and 21).
The results of antifungal activity of tested compounds
against eight fungi are presented in Table 2. It can be seen that
all compounds exhibited antifungal effect. MIC is in range of
3.67–34.6 * 10
2 lmol/mL and MFC in 7.35–39.6 * 10
2
lmol/mL. The antifungal potential could be presented as:
18 > 24 > 19 > 20 > 23 > 17 > 25 > 16 > 22 > 21 > 15.
Compound 18 again showed the best antifungal activity
among other tested compounds with MIC at 3.67–9.80 * 10
2
lmol/mL and MFC at 7.35–19.6 * 10
2 lmol/mL. Compound
24 is the next one with strong antifungal activity with MIC at
11.3–22.6 * 10
2 lmol/mL and MFC 11.3–31.6 * 10
2 lmol/
mL, while compound 15 possessed the lowest antifungal poten-
tial with inhibitory activity at 13.2–21.1 * 10
2 lmol/mL and
fungicidal activity at 21.1–39.6 * 10
2 lmol/mL. The majority
of the compounds presented the best activity against Aspergil-
lus ochraceus, Aspergillus versicolor and Aspergillus fumigatus,
while Candida albicans was the most resistant species to the
compounds. The commercial antifungal agent, bifonazole,
showed MIC at 32.0–64.0 * 10
2 lmol/mL and MFC at
48.0–80.0 * 10
2 lmol/mL. Ketoconazole showed fungistatic
activity at 38.0–475.0 * 10
2 lmol/mL and fungicidal effect
at 95.0–570.0 * 10
2 lmol/mL. All the tested compounds
showed better fungistatic effect than bifonazole and ketocona-
zole. Some of the compounds did not exhibit fungicidal activ-
ity in tested concentration against Aspergillus niger,
Trichoderma and C. albicans. Compound 18 showed the best
effect against bacteria and fungi, while compound 2 exhibited
the worst activity against all the tested microorganisms.
It was observed that compounds that exhibited the lowest
antibacterial activity are 1–9 (Table 1). The antibacterial
potential of this group could be presented as follows:
4 > 8 > 9> 7> 5 > 3 > 6> 1 and 2. The majority of com-
pounds did not affect some bacteria, such as M. flavus, E. coli,
and Enterobacter cloacae. The compound 4 with highest
antibacterial activity showed inhibitory effect at 98.0–
490.0 * 10
2 lmol/mL bactericidal at 490.0 * 10
2 lmol/mL.
Compound 2 inhibited bacterial growth with lowest potential
at 100.72–377.7 * 10
2 lmol/mL, while bactericidal effect was
achieved at 214.4–805-76 * 10
2 lmol/mL. This compoundPlease cite this article in press as: Tratrat, C. et al., Design, synthesis and biological
azol-6(5H)ones. Pharmacophore models for antifungal activity. Arabian Journal ofshowed the lowest antibacterial activity among all the others.
Streptomycin and Ampicillin showed better antibacterial activ-
ity than this group of compounds. Antifungal potential of
compounds from this group could be presented as follows:
5 > 4 > 2 > 3> 8> 1 > 7 > 9> 6 (Table 2). Compound
5 showed the best antifungal potential with inhibitory concen-
tration at 6.15–24.6 * 10
2 lmol/mL and fungicidal at 24.6–
98.4 * 10
2 lmol/mL. Compound 4 showed also very good
antifungal potential with inhibitory concentration at 6.12–
24.5 * 10
2 lmol/mL and fungicidal at 49.0–171.5 * 10
2
lmol/mL. The lowest antifungal effect was achieved for com-
pound 6 with MIC at 6.3–75.9 * 10
2 lmol/mL and MFC at
75.9–177.1 * 10
2 lmol/mL. Only compounds 7, 8, 9, 6, 2,
and 4 exhibited antifungal potential against C. albicans. The
majority of compounds showed higher antifungal potential
than commercial fungicides (Table 2).
The next group of compounds are compounds 10–14
(Table 1). They showed higher antimicrobial activity than pre-
vious one. The best activity in this group is seen for compounds
13 and 14 with MIC at18.6–92.8 * 10
2 lmol/mL  102 and
23.2–92.8 * 10
2 lmol/mL  102 and MBC at 946.4–
185.6 * 10
2 lmol/mL. Compounds 10 and 11 showed slightly
higher antibacterial activity than previous one, while 12was the
less active with MIC and MBC values (125.9–377.7  102
lmol/mL and 200.8–503.6  102 lmol/ml * 102). Antifungal
activity for these compounds presented in Table 2 could be pre-
sented as follows: 10 > 14 > 13 > 11> 12. The best antifun-
gal activity is seen for compound 10 which possessed MIC at
6.1–170.8 * 10
2 lmol/mL and MFC at 24.4–97.6 * 10
2
lmol/mL. Compound 12 as in the case of antibacterial activity
showed the worst antifungal potential with MIC at 6.28–
175.7 * 10
2 lmol/mL and MFC at 25.1–175.7 * 10
2 lmol/
mL. Almost all compounds in this group showed better anti-
fungal potential than ketoconazole, with exception of com-
pounds 11 and 12 against A. fumigatus, compounds 10, 12,
13, 14 against A. niger and C. albicans. Bifonazole showed
lower antifungal effect than compounds from this group
toward all fungi, except A. fumigatus, A. niger and C. albicans.
It can be seen that the third group of compounds 15–25
possessed the highest antibacterial and antifungal potential
and did not affect E. faecalis at all, and only 22 against C. albi-
cans. Second group of compounds (10–14) showed lower activ-
ity than previous one, and did not exhibit potential on E.
cloacae and C. albicans. The lowest antimicrobial potential
could be seen for third group of compounds 1–9 which showed
high MIC and MBC/MFC. These compounds did not exhibit
activity toward E. coli and E. cloacae, and C. albicans fromevaluation of new substituted 5-benzylideno-2-adamantylthiazol[3,2-b][1,2,4]tri-
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8 C. Tratrat et al.fungi. It is obvious that all three groups of compounds showed
at first different level of antibacterial and antifungal activity
and then they were inactive against different bacterial and
fungal species. The reason of such activity could be because
of different mechanisms of action of different derivatives influ-
enced by different chemical groups.
2.2.1. Statistical analysis
For each species, three samples were used and all the assays
were carried out in triplicate. The results were expressed as
mean values and standard errors, and analyzed using one-
way analysis of variance (ANOVA) followed by Tukey’s
HSD Test with a= 0.05. This analysis was carried out using
the SPSS v. 18.0 software.
2.3. Elucidating the relation of molecular properties to
antimicrobial activity
Physically significant descriptors and pharmaceutically rele-
vant properties were predicted using the QikProp software.
Then multivariate data analysis was implemented to elucidate
the relation between molecular properties to antimicrobial and
antifungal activities of the synthesized compounds. Specifi-Figure 1 PCA model A= 2, N= 25, R2X(cum) = 0.92, Q2(cum) =
groups (Group1: circles; Group 2: squares) B. Loading scatter plot di
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compound 18 is the optimum against most of the tested strains
as it yields the highest antibacterial and antifungal activities.
Therefore, the objective was to determine the physically signif-
icant descriptors and pharmaceutically relevant properties of
any other synthesized compound that resembles its antibacte-
rial and antifungal fingerprints.
For this purpose a PCA model was extracted in order to
discern from the scores plot the synthesized compounds that
localize near compound 18 and identify from the loading plot
the molecular properties that mainly characterize them. The
PCA model (A= 2, N= 25, R2X(cum) = 0.92, Q2(cum)
= 0.83) was extracted based only on the physicochemical
properties of the synthesized compounds (Fig. 1). The forma-
tion of two groups is evident along the PC1 principal compo-
nent. Compound 18 belongs to Group 1 together with 17, 5,
10, 11, 4, 7, 9,19, 8, 6, 16 and 17. This suggests that these mole-
cules probably exhibit similarly potent biological activities
explained by some common descriptors. The loading plot high-
lights the descriptors which contribute to the clustering
between the two groups. From these, the most significant are
the (a) number of non-trivial (not CX3), non-hindered (not
alkene, amide, small ring) rotatable bonds (#rotor), (b) total0.83. A. Scores scatter plot depicting a clear separation into two
splaying the variables that characterize each group.
evaluation of new substituted 5-benzylideno-2-adamantylthiazol[3,2-b][1,2,4]tri-
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Pharmacophore models for antifungal activity 9solvent accessible surface area (SASA) in square angstroms
using a probe with a 1.4 A radius, (c) hydrophobic component
of the SASA(FOSA), (d) hydrophilic component of the SASA
(FISA), (e) total solvent-accessible volume in cubic angstroms
using a probe with a 1.4 A˚ radius (volume), (f) estimated aver-
age number of hydrogen bonds (taken over a number of con-
figurations) that would be donated by the solute to water
molecules in an aqueous solution (HBd), (g) estimated average
number of hydrogen bonds (taken over a number of configura-
tions)that would be accepted by the solute from water mole-
cules in an aqueous solution (HBa), (h) hexadecane/gas
partition coefficient (QPlogPC16), (i) octanol/gas partition
coefficient (QPlogPoct), (j) water/gas partition coefficient
(QPlogPw), (k) predicted brain/blood partition coefficient
(QPlogBB), (l) predicted skin permeability (QPlogKp), (m)
number of likely metabolic reactions (#metab), (n) Van der
Waals surface area of polar nitrogen and oxygen atoms and
carbonyl carbon atoms (PSA), (o) number of nitrogen and
oxygen atoms (#NandO), (p) number of heavy atoms (#non-
Hatm). These produced values can be further used as descrip-
tors for QSAR and in silico screening techniques.
2.4. Generation of pharmacophore model for antifungal activity
The generation of the pharmacophore model using a training
set of six compounds (8, 16, 18, 19, 23 and 25) resulted inTable 3 The pharmocophoric features generated.
Hypo Featurea Rankb Direct hitc Partial hitd
A. fumigatus
1 RHHAAA 94.84 101111 010000
2 RHHAAA 94.84 101111 010000
3 RHHAAA 94.28 101111 010000
4 RHHAAA 93.99 101111 010000
5 RHHAAA 91.68 101111 010000
6 RHHAAA 90.94 101111 010000
7 RHHAAA 90.15 101111 010000
8 RHHAAA 88.52 101111 010000
9 RHHAAA 88.52 101111 010000
10 RHHAAA 87.3 101111 010000
C. albicans
1 RHHAAA 94.84 101111 010000
2 RHHAAA 94.84 101111 010000
3 RHHAAA 92.10 101111 010000
4 RHHAAA 90.94 101111 010000
5 RHHAAA 88.83 101111 010000
6 RHHAAA 87.42 101111 010000
7 RRHHA 81.14 101111 010000
8 RRHHA 81.14 101111 010000
9 RRHHA 81.14 101111 010000
10 RHHAA 80.51 101111 010000
a R = Ring Aromatic group; H = Hydrophobic aliphatic group;
A = Hydrogen bond acceptor group.
b Higher ranking score indicate less probability that the molecules
in the training set fit the hypothesis by a chance correlation. The
best hypotheses have the highest ranking score.
c Direct Hit = all the features are mapped. Direct Hit = 1 means
yes.
d Partial Hit = partial mapping of the hypothesis. Partial
Hit = 0 means No.
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cophore features as depicted in Table 3 for A. fumigatus and C.
albicans.
It was interesting to note that the top two hypothesis
(Hypo1 and Hypo2) in both species (A. fumigatus & C. albi-
cans) had exactly the same pharmacophoric features
(RHHAAA) suggesting possibly the same target in both these
species. Both these hypothesis (hypo1 and Hypo2) in both spe-
cies (A. fumigatus & C. albicans) also showed same ranking
score of 94.84 and were constituted by two HAl(HAl1 and
HAl2), three HBA(HBA1, HBA2 and HBA3) and one (RA)
features. All the ten generated hypotheses in case of A. fumi-
gatus were found to be uniform regarding the composition of
chemical features. However in case of C. albicans the first five
hypotheses were found to be uniform in terms of pharma-
cophore feature composition. The Hypo1 for both A. fumiga-
tus and C. albicans having same chemical feature composition
(RHHAAA) showed similar chemical feature mapping for the
most active compound 18. The preliminary pharmacophore
models in both the species (A. fumigatus and C. albicans) were
further refined by addition of excluded volumes for identifica-
tion of the least active compounds in the series properly. As
an optimization strategy the HAl1 feature was also modified
to have a location sphere radius of 2.5 A˚ in both cases
(A. fumigatus and C. albicans) to make improvements in pre-
diction. The location sphere radius for the excluded volumes
were optimized and reduced to lower values so as to assign
better fit values for the active compounds and lower fit values
for the least active compounds in the series. In both CFPM
compound 18 (Fig. 2a & c) was observed to map the HAl1
with the 3-methoxy group attached to the phenyl ring while
the adamantyl group present at the other terminal mapped
the HAl2 feature. The threes HBA features generated mapped
the thiazole sulfur atom (HBA1), the ketooxygen atom
(HBA2) and the triazole nitrogen atom (HBA3) while the
RA feature generated mapped the phenyl ring of compound
18 (Fig. 2a & c). The distance matrix of pharmacophore fea-
tures for Hypo1 for both A. fumigatus and C. albicans were
found to be the same and has been presented in supporting
information (Table 3). The least active compound 6 in the ser-
ies of A. fumigatus mapped all the features of the pharma-
cophore (CFPM of A. fumigatus) with the same functional
groups as observed for compound 18 except HAl1 as the
compound lacks a hydrophobic feature at this position
(Fig. 2b). A similar mismatch with the HAl1 was also
observed for the least active compound 2 in the series for C.
albicans (CFPM of C. albicans) (Fig. 2d). The pharmacophore
fit values (Supplementary information: Table 2) obtained from
the CFPM were further correlated with biological activity
(pMIC) of the compounds for each species. The generated
CFPM for A. fumigatus was found to have a correlation value
(R) of 0.51(n= 25) between observed activity (pMIC) and
pharmacophore fit values that improved to 0.74 (n= 23)
when two outliers (5, 23) were removed from the series
(Fig. 2e). In case of C. albicans similar improvement
(n= 18, R= 0.48; n= 16, R= 0.74) (Fig. 2f) was observed
when two outliers (20, 23) were removed from the series that
indicate the generated pharmacophore models have good abil-
ity to predict the individual antifungal activity in these series
of compounds.evaluation of new substituted 5-benzylideno-2-adamantylthiazol[3,2-b][1,2,4]tri-
Chemistry (2016), http://dx.doi.org/10.1016/j.arabjc.2016.06.007
Figure 2 (a). Mapping of the most active compound 18 with the CFPM of A. fumigatus. (b) Mapping of the least active compound 6
with the CFPM of A. fumigatus. (c) Mapping of the most active compound 18 with the CFPM of C. albicans. (d) Mapping of the least
active compound 18 with the CFPM of C. albicans. (e) Graph displaying correlation between observed activity (pMIC) and
pharmacophore fit value for (e) A. fumigatus (f) C. albicans. All the excluded volumes have location sphere of radius of 0.8 A˚ except those
mentioned in the figure. The HAl1 has a location sphere of radius 2.5 A˚.
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In summary this study proposes twenty-five novel compounds as puta-
tive novel antimicrobials. Particularly, a series of novel 5-benzylideno-
2-adamantylthiazol [3,2-b][1,2,4]triazol-6(5H)ones were synthesized
and evaluated in vitro for their antimicrobial properties against Gram
positive, Gram negative bacteria and fungi strains.
Almost all the tested compounds showed antibacterial activity but
on different level and this activity was even better than that of Strep-
tomycin against L. monocytogenes, and E. coli. All compounds showed
antifungal effect with MIC in range of 3.67–34.6 * 10
2 lmol/mL and
MFC in 7.35–39.6 * 10
2 lmol/mL. The majority of the compounds
showed the best activity against A. ochraceus, A. versicolor and A.
fumigatus, while C. albicans was the most resistant species to the com-
pounds. All the compounds tested showed better fungistatic effect than
bifonazole and ketoconazole. It was observed that the best antifungal
activity was observed for compounds 15–25. Compounds 10–13 and 14
were less active than the previous ones, while the lowest activity was
expressed by the rest of compounds. The application of multivariate
data analysis suggested the physically significant descriptors and prop-
erties that result in the optimum antibacterial and antifungal finger-
prints for the examined compounds. In light of this, the highlighted
parameters can be further used as descriptors for QSAR and in silico
screening techniques.
Moreover, for A. fumigatus and C. albicans the generation of phar-
macophore was performed. It was interesting to note that both species
(A. fumigatus & C. albicans) had exactly the same pharmacophoricPlease cite this article in press as: Tratrat, C. et al., Design, synthesis and biological
azol-6(5H)ones. Pharmacophore models for antifungal activity. Arabian Journal offeatures (RHHAAA) suggesting possibly the same target in both these
species. The results indicated that generated pharmacophore models
have good ability to predict the individual antifungal activity in these
series of compounds in case of C. albicans.4. Experimental section
4.1. Chemistry-general aspects
Melting points (C) were determined with a MELTEMP II
capillary apparatus (LAB Devices, Holliston, MA, USA) with-
out correction. Elemental analyses were performed on a Per-
kin–Elmer 2400 CHN elemental analyzer and for all
compounds synthesized were within a 0.4% of theoretical val-
ues. IR spectra were recorded, as Nujol mulls, on a Perkin
Elmer Spectrum BX. Wave numbers in the IR spectra are
given in cm1. 1H NMR and 13C NMR spectra of the newly
synthesized compounds, in DMSO-d6 or CDCl3 solutions,
were recorded on a Bruker AC 300 instrument (Bruker, Karl-
sruhe, Germany) at 298 K. Chemical shifts are reported as d
(ppm) relative to TMS as internal standard. Coupling con-
stants J are expressed in Hertz (Center of Instrumental Analy-
sis of the University of Thessaloniki). The reactions were
monitored by TLC on F254 silica-gel precoated sheets (Merck,evaluation of new substituted 5-benzylideno-2-adamantylthiazol[3,2-b][1,2,4]tri-
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showed a single spot. Solvents, unless otherwise specified were
of analytical reagent grade or of the highest quality commer-
cially available. Synthetic starting materials, reagents and sol-
vents were purchased from Aldrich Chemie (Steinheimm,
Germany).
4.2. Synthesis of 1-(1-adamantanocarbonylo)thiosemicarbazide
(Tozkoparan et al., 2000)
To a solution of thiosemicarbazide (0.1 mol, 9.1 g) in dry pyr-
idine (150 ml), a solution of 1-adamantylcrabonyl chloride
(0.1 mol, 19.869 g) in dry benzene (150 ml) under stirring and
temperature at 5 C was added. The reaction mixture was
stirred for another 0.5 h at 5 C and after left at room tem-
perature for 12 h. After removal of solvents, to the remain
solid water was added and precipitate was filtered and recrys-
tallized from methanol: dichloromethane. Yield: 70%.
4.3. Synthesis of 5-adamantyl-4H-1,2,4-triazol-3-thiol
((Tozkoparan et al., 2000)
To a solution of NaOH 5% (5 ml) 1-(1-adamantanocarbonylo)
thiosemicarbazide (0.01 mol) was added and reaction mixture
was refluxed for 2 h. After cooling to reaction mixture HCl
10% was added till pH = 6. The precipitate washed with water
and filtered. Dry product recrystallized from methanol. Yield,
93%.IR: (cm1, Nujol): 3554 (NH), 2670 (SH), 1579 (C‚N).
1H NMR: (d ppm, DMSO-d6, 300 MHz): 1.70–2.51 (m, 15H,
adamantane).
4.4. General method for preparation of 5-aryliden -2-
adamatylthiazol[3,3-b]triazol-6(5H)-ones (Vicini et al., 2008)
To a solution of 5-adamantyl-4H-1,2,4-triazol-3-thiol (4 mol)
in acetic acid (10 ml), bromoacetic acid (6 mol), appropriate
aromatic aldehyde (4 mol), sodium acetate (0.54 gr,
6.58 mmol) and acetic anhydride (8 ml) were added. The reac-
tion mixture was refluxed under stirring for 6 h. The obtained
product left for some hours at room temperature and after
pawed to the ice. The obtained precipitate filtered and recrys-
tallized from dioxane.
4.4.1. 2-Adamantyl-5-(benzyliden)thiazol[3,2-b][1,2,4]triazol-
6(5H)-one (1)
Yield: 42%, m.p. 203–205 C, Rf = 0.63 (toluene-ethanol 8:2),
1H NMR:(DMSO-d6) d (ppm): 1.75–2.05 (m, 15H, adaman-
tan),7.59–7.61 (m, 2H, ArAH), 7.74–7.77 (m, 3H, ArAH),
8.22 (s, 1H, CH‚). MS (m/z, I%): (M+ + 1) 364 (12%),
356 (76%), 330 (100%), 314 (68%), 284 (20%), 268 (36%),
184 (16%), 165 (24%), 125 (16%), 107 (24%). Anal. Calc.
for C21H21N3OS (MW 363): C: 69.39; H: 5.82; N: 11.56%.
Found: C: 69.41; H: 5.80; N: 11.53%.
4.4.2. 2-Adamantyl- 5-(3-hydroxybenzyliden)thiazol[3,2-b]
[1,2,4]triazol-6(5H)-one (2)
Yield: 63%, m.p. 239–241 C (dioxan), Rf = 0.75 (toluene-
ethanol 8:2), IR:(cm1, Nujol): 1734 (C‚O), 1608 (C‚N).
1H NMR: (d ppm, CDCl3, 300 MHz): 1.82–2.36 (m, 15H,
adamantan), 7.28 (s, 1H, ArAH), 7.35–7,38 (m, 1H, ArAH),Please cite this article in press as: Tratrat, C. et al., Design, synthesis and biological
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(s, 1H, CH‚). Anal. Calcd. for C21H21N3O2S(MW 379): C:
66.47; H: 5.58; N: 11.07%. Found: C 66.61; H 6.00; N:
10.98%.
4.4.3. 2-Adamantyl -5-(4-hydroxybenzyliden)thiazol[3,2-b]
[1,2,4]triazol-6(5H)-one (3)
Yield: 80%, m.p. 238–240 C (ethanol), Rf = 0.7 (toluene-
ethanol 8:2), IR: (cm1, Nujol): 1736 (C‚O), 1595 (C‚N).
1H NMR: (d ppm, CDCl3, 300 MHz): 1.76–2.31 (m, 15H,
adamantan), 7.38 (d, J= 6 Hz, 2H, ArAH), 7.80 (d,
J= 9 Hz, 2H, ArAH), 8.22 (s, 1H, CH‚). MS: (m/z): 379
(M+, 18%), 378 (100%), 285 (4%), 283 (53%), 255 (60%),
241 (6%), 235 (19%), 234 (86%), 233 (31%), 218 (3%), 191
(3%). Anal. Calcd for C21H21N3O2S (MW 379):C: 66.47, H:
5.58, N: 11.07%. Found: C:66.55; H:5.56; N: 11.02%.
4.4.4. 2-Adamantyl-5-(4-methoxybenzyliden)thiazol[3,2-b]
[1,2,4]triazol-6(5H)-one (4)
Yield: 71%, m.p. 250–252 C (ethanol), Rf = 0.31 (toluene-
ethanol 9.5:0.5), IR: (cm1, Nujol): 1734 (C‚O), 1608
(C‚N). 1H NMR: (d ppm, CDCl3, 300 MHz): 1.76–2.07 (m,
15H, adamantan), 3.88 (s, 3H, OCH3), 7.18 (d, J= 9 Hz,
2H, ArAH), 7.74 (d, J= 9 Hz, 2H, ArAH), 8.19 (s,1H,
CH‚). Anal. Calcd. forC22H23N3O2S: C: 67.15; H: 5.89; N:
10.68%. Found: C: 67.26; H: 5.92; N: 10.65%.
4.4.5. 2-Adamantyl-5-(2,4-dihydroxybenzyliden)thiazol[3,2-b]
[1,2,4]triazol-6(5H)-one (5)
Yield: 38%, m.p. 230–232 C (ethanol), Rf = 0.66 (toluene-
ethanol 8:2), IR: (cm1, Nujol): 1739 (C‚O), 1608 (C‚N).1H
NMR: (d ppm, CDCl3, 300 MHz): 1.72–2.04 (m, 15H,
adamantan), 8.34 (s,1H, CH‚). MS (m/z, I%): (M+ + 1)
396 (11%), 387 (18%), 386 (100%), 229 (17%), 203
(22%),165 (67%), 157 (17%), 135 (39%). Anal. Calcd. for C21-
H21N3O3S (MW 395):C: 63.78; H: 5.35; N: 10.62%. Found: C:
63.82; H: 5.40; N: 10. 60%.
4.4.6. 2-Adamantyl-5-(2-hydroxy-3-methoxybenzyliden)thiazol
[3,2-b][1,2,4]triazol-6(5H)-one (6)
Yield: 55%, m.p. 234–236 C (ethanol), Rf = 0.63 (toluene-
ethanol 8:2), IR: (cm1, Nujol): 1733 (C‚O), 1607 (C‚N).
1H NMR: (d ppm, CDCl3, 300 MHz): 1,75–2.03 (m, 15H
adamantan), 4.01 (s, 3H, OCH3),7.10–7.17 (m, 2H, ArAH),
7.25–7.30 (m, 1H, ArAH). Anal. Calcd. for C22H23N3O3S
(MW 409): C: 64.53; H: 5.66; N:10.26%. Found:C: 64.60; H:
5.51; N: 10.31%.
4.4.7. 2-Adamantyl-5-(4-hydroxy-3-methoxybenzyliden)thiazol
[3,2-b][1,2,4]triazol-6(5H)-one (7)
Yield: 58%, m.p. 263–265 C (ethanol), Rf = 0.67 (toluene-
ethanol 8:2), IR: (cm1, Nujol):) 1724 (C‚O), 1578 (C‚N.
1H NMR: (d ppm, CDCl3, 300 MHz): 1.77–2,30 (m, 15H,
adamantan), 3.87 (s, 3H, OCH3), 7.35 (s, 2H, ArAH), 7.54
(s, 1H, ArAH), 8.23 (s, 1H, CH‚).
MS: (m/z): 409 (M+, 1,3%), 408 (8%), 393 (2%), 255
(7%), 234 (100%), 235 (15%), 233 (31%), 207 (4%), 2020
(2.5%). Anal. Calcd. for C22H23N3O3S (MW): C: 64.53; H:
5.66; N: 10.26%. Found: C: 64.50; H: 5.7; N: 9.98%.evaluation of new substituted 5-benzylideno-2-adamantylthiazol[3,2-b][1,2,4]tri-
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[1,2,4]triazol-6(5H)-one (8)
Yield: 62%, m.p. 249–251 C (ethanol), Rf = 0.56 (toluene-
ethanol 8:2), IR: (cm1, Nujol): 1723 (C‚O), 1590 (C‚N).
1H NMR: (d ppm, CDCl3, 300 MHz): 1,75–2,05 (m, 15H,
adamantan), 3.85 (s, 6H, OCH3), 7,20 (s, 1H, ArAH), 7.35–
7.38 (m, 2H, ArAH), 8.18 (s, 1H, CH‚).MS (m/z, I%):
(M++ 1) 424 (40%), 165 (100%), 135 (30%). Anal. Calcd.for
C23H25N3O3S (MW 423):C: 62.23; H: 5.95; N: 9.92%. Found:
62.35, H: 5.55, N: 9.82%.
4.4.9. 2-Adamantyl-5-(4-hydroxy-3,5-dimethoxybenzyliden)
thiazol[3,2-b][1,2,4]triazol-6(5H)-one (9)
Yield: 88%, m.p. 263–265 C (ethanol), Rf = 0.67 (toluene-
ethanol 8:2), IR: (cm1, Nujol):) 1724 (C‚O), 1578 (C‚N.
1H NMR: (d ppm, CDCl3, 300 MHz): 1.77–2.30 (m, 15H,
adamantan), 3.87 (s, 3H, OCH3), 7.35 (s, 2H, ArAH), 7.54
(s, 1H, ArAH), 8.23 (s, 1H, CH‚). Anal. Calcd. for C23H25-
N3O4S (MW 439): C: 62.85; H:5.73; N: 9.56%. Found: C:
62.92; H: 5.80; N: 9.61%.
4.4.10. 2-Adamantyl-5-(3,4,5-trimethoxybenzyliden)thiazol
[3,2-b][1,2,4]triazol-6(5H)-one (10)
Yield: 67%, m.p. 305–307 C (ethanol), Rf = 0.57 (toluene-
ethanol 8:2), IR:(cm1, Nujol):) 1729 (C‚O), 1603 (C‚N).
1H NMR: (d ppm, CDCl3, 300 MHz): 1.59–2.11 (m, 15H,
adamantan), 3.94 (s, 9H, OCH3), 6.85 (s, 2H, ArAH), 8.12
(s, 1H, CH‚). MS (m/z, I%): (M+ + 1) 409 (27%), 357
(8%), 356 (26%), 338 (26%), 317(24%), 316 (100%), 314
(43%), 298 (18%), 294 (39%), 293 (37%), 276 (74%), 248
(43%), 204 (13%), 174 (44%), 165 (38%), 135 (13%), 125
(39%). Anal. Calcd. for C24H27N3O4S (MW 453):C: 63.56;
H: 6.0; N: 9.26%. Found: C: 63.49; H: 6.21; N: 9.32%.
4.4.11. 2-Adamantyl-5-(4-dimethylaminobenzyliden)thiazol
[3,2-b][1,2,4]triazol-6(5H)-one (11)
Yield: 69%, m.p. 267–268 C (ethanol), Rf = 0.63 (toluene-
ethanol 8:2), IR:(cm1, Nujol):) 1728 (C‚O), 1586 (C‚N).
1H NMR: (d ppm, CDCl3, 300 MHz): 1.75–2.05 (m, 15H,
adamantan), 3.07 (s, 6H, CH3), 6.87 (d, J= 9 Hz, 2H, ArAH),
7.60 (d, 2H, J= 8.7 Hz, ArAH), 8.08 (s, 1H, CH‚). MS (m/z,
I%): (M++ 1) 409 (41%), 165 (100%), 135 (59%). Anal.
Calcd. for C23H26N4OS (MW 406): C: 67.95; H: 6.45; N:
13.78%. Found: C: 68.02; H: 6.28; N: 13.55%.
4.4.12. 5-(2-nitrobenzyliden)thiazol[3,2-b][1,2,4]triazol-6
(5H)-one (12)
Yield: 47%, m.p. 159–161 C (ethanol), Rf = 0.68 (toluene-
ethanol 8:2), IR: (cm1, Nujol):) 1749 (C‚O), 1625 (C‚N).
1H NMR: (d ppm, CDCl3300 MHz): 1.75–2.06 (m, 15H,
adamantan), 7.79–7.93 (m, 2H, ArAH), 7.95–7.98 (m, 3H,
ArAH), 8.29 (d, 1H, J= 8.1 Hz, ArAH), 8.49 (s, 1H,
CH‚). MS (m/z, I%): (M+ + 1) 398 (5%), 338 (56%), 304
(32%), 248 (40%), 165 (100%), 135 (60%). Anal. Calcd. for
C21H20N4O8S (MW 406): C: 61.75; H: 4.94; N: 13.72%.
Found: C: 61.91; H: 5.02; N: 13. 57%.
4.4.13. 5-(3-nitrobenzyliden)thiazol[3,2-b][1,2,4]triazol-6
(5H)-one (13)
Yield: 49%, m.p. 205–207 C (ethanol), Rf = 0.78 (toluene-
ethanol 8:2), IR: (cm1, Nujol):) 1739 (C‚O), 1608 (C‚N).Please cite this article in press as: Tratrat, C. et al., Design, synthesis and biological
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adamantan), 7.87–7.92 (m, 1H, ArAH),8.14 (d, 1H,
J= 7.8 Hz, ArAH), 8.355 (s, 1H, ArAH), 8.36 (s, 1H,
CH‚), 8.59 (s, 1H, ArAH). Anal. Calcd. for C21H20N4O8S
(MW 406): C: 61.75; H: 4.94; N: 13.72%. Found: C: 61.86;
H:4.87; N: 13. 68%.
4.4.14. 5-(4-nitrobenzyliden)thiazol[3,2-b][1,2,4]triazol-6
(5H)-one (14)
Yield: 59%, m.p. 176–178 C (ethanol), Rf = 0.36 (toluene-
ethanol 8:2), IR: (cm1, Nujol):) 1718 (C‚O), 1608 (C‚N).
1H NMR: (d ppm, CDCl3, 300 MHz): 1.7–2.0 (m, 15H,
adamantan), 7.94 (d, 2H, J= 8.7 Hz, ArAH), 8.01 (s, 1H,
CH‚), 8.28 (d, J= 8.7 Hz, 2H, ArAH). Anal. Calcd. for C21-
H20N4O8S (MW 406): C: 61.75; H: 4.94; N: 13.72%. Found: C:
61.78; H:4.90; N: 13. 70%.
4.4.15. 5-(3-fluorobenzyliden)thiazol[3,2-b][1,2,4]triazol-6
(5H)-one (15)
Yield: 71%, m.p. 193–195 C (ethanol), Rf = 0.46 (toluene-
ethanol 8:2), IR: (cm1, Nujol):) 1740 (C‚O), 1612 (C‚N).
1H NMR: (d ppm, CDCl3, 300 MHz): 1.75–2.06 (m, 15H,
adamantan), 7.40–7.46 (m, 1H, ArAH), 7.59–7.70 (m, 3H,
ArAH), 8.22 (s, 1H, CH‚). Anal. Calcd. for C21H20FN3OS:
C: 66.12; H: 5.28; N: 11.02%. Found: 66.42; H: 5.7; N:
10.93%.
4.4.16. 5-(4-fluorobenzyliden)thiazol[3,2-b][1,2,4]triazol-6
(5H)-one (16)
Yield: 66%, m.p. 238–240 C (ethanol), Rf = 0.73 (toluene-
ethanol 9:1), IR:(cm1, Nujol): 1737 (C‚O), 1595 (C‚N). 1H
NMR: (d ppm, CDCl3, 300 MHz): 1.77–2.12 (m, 15H, adaman-
tan), 7.22–7.25 (m, 2H, ArAH), 7.60–7.65 (m, 2H, ArAH), 8.17
(s, 1H, CH‚). Anal. Calcd. for C21H20FN3OS: C: 66.12; H:
5.28; N: 11.02%. Found: 65.99; H: 5.23; N: 10.82%.
4.4.17. 5-(2-chlorobenzyliden)thiazol[3,2-b][1,2,4]triazol-6
(5H)-one (17)
Yield: 48%, m.p. 246–248 C (ethanol), Rf = 0.64 (toluene-
ethanol 8:2), IR: (cm1, Nujol): 1743 (C‚O), 1607 (C‚N).
1H NMR: (d ppm, CDCl3, 300 MHz): 1.82–2.11 (m, 15H,
adamantan), 7.43–7.48 (m, 1H, ArAH), 7.54–7.57 (m, 1H,
ArAH), 7.64–7.67 (m, 1H, ArAH), 8.54 (s, 1H, CH‚). Anal.
Calcd. for C21H20ClN3OS (MW 3.97): C:63.39; H: 5.07; N:
10.56%. Found: C: 63.55; H: 5.13; N: 10.49%.
4.4.18. 5-(3-chlorobenzyliden)thiazol[3,2-b][1,2,4]triazol-6
(5H)-one (18)
Yield: 47%, m.p. 193–195 C (ethanol), Rf = 0.57 (toluene-
ethanol 8:2), IR: (cm1, Nujol): 1740 (C‚O), 1607 (C‚N).
1H NMR: (d ppm, CDCl3, 300 MHz): 1.76–2.06 (m, 15H,
adamantan), 7.65–7.70 (m, 3H, ArAH), 7.83 (s, 1H, ArAH),
8.22 (s, 1H, CH‚). Anal. Calcd. for C21H20ClN3OS (MW
397): C:63.39; H: 5.07; N: 10.56%. Found: C: 63.45; H: 5.12;
N: 10.60%.
4.4.19. 5-(4-chlorobenzyliden)thiazol[3,2-b][1,2,4]triazol-6
(5H)-one (19)
Yield: 51%, m.p. 242–244 C (ethanol), Rf = 0.69 (toluene-
ethanol 9:1), IR: (cm1, Nujol): 1731 (C‚O), 1604 (C‚N).evaluation of new substituted 5-benzylideno-2-adamantylthiazol[3,2-b][1,2,4]tri-
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adamantan), 7.68 (d, J= 8.7 Hz, 2H, ArAH), 7.77 (d,
J= 8.4 Hz, 2H, ArAH), 8.23 (s, 1H, CH‚). Anal. Calcd.
for C21H20ClN3OS (MW 397): C:63.39; H: 5.07; N: 10.56%.
Found: C: 63.41; H: 5.04; N: 10.50%.
4.4.20. 5-(2,3-dichlorobenzyliden)thiazol[3,2-b][1,2,4]triazol-
6(5H)-one (20)
Yield: 87%, m.p. 201–203 C (ethanol), Rf = 0.53 (CHCl3),
IR: (cm1, Nujol): 1739 (C‚O), 1654 (C‚N). 1H NMR: (d
ppm, CDCl3, 300 MHz): 1.82–2.11 (m, 15H, adamantan),
7.39–7.45 (m, 1H, ArAH), 7.54 (d, J= 7,8 Hz, 1H, ArAH),
7.64 (d, J= 8,1 Hz, 1H, ArAH), 7.75 (s,1H, ArAH), 8.11 (s,
1H, CH‚). Anal. Calcd. for C21H19Cl2N3OS (MW432):C:
58.34, H: 4.43, N: 9.72%. Found:C: 58.42, H: 4.41, N: 9.65%.
4.4.21. 5-(2,4-dichlorobenzyliden)thiazol[3,2-b][1,2,4]triazol-
6(5H)-one (21)
Yield: 51%, m.p. 203–205 C (ethanol), Rf = 0.53 (toluene-
ethanol 8:2), IR: (cm1, Nujol): 1740 (C‚O), 1578 (C‚N).
1H NMR: (d ppm, CDCl3, 300 MHz): 1.82–2.10 (m, 15H,
adamantan), 7.41–7.48 (m, 1H, ArAH), 7.54–7.62 (m, 2H,
ArAH), 8.45 (s, 1H, CH‚). Anal. Calcd. for C21H19Cl2N3OS
(MW432): C: 58.34, H: 4.43, N: 9.72%. Found:C: 58.30, H:
4.46, N: 9.68%.
4.4.22. 5-(2,6-dichlorobenzyliden)thiazol[3,2-b][1,2,4]triazol-
6(5H)-one (22)
Yield: 53%, m.p. 203–205 C (ethanol), Rf = 0.74 (toluene-
ethanol 8:2), IR:(cm1, Nujol): 1751 (C‚O), 1628 (C‚N).
Anal. Calcd. for C21H19Cl2N3OS (MW432):C: 58.34, H:
4.43, N: 9.72%. Found: C: 58.29, H: 4.38, N: 9.73%.
4.4.23. 5-(2-bromobenzyliden)thiazol[3,2-b][1,2,4]triazol-6
(5H)-one (23)
Yield: 55%, m.p. 249–251 C (dioxan), Rf = 0.43 (CHCl3), IR:
(cm1, Nujol): 1742 (C‚O), 1607 (C‚N). 1H NMR: (d ppm,
CDCl3, 300 MHz):1.82–2.11 (m, 15H, adamantan), 7.32–7.38
(m, 1H, ArAH), 7.46–7.51 (m, 1H, ArAH), 7.62 (d,
J= 7,8 Hz, 1H, ArAH), 7.74 (d, J= 7,95 Hz, 1H, ArAH),
8.48 (s, 1H, CH‚). Anal. Calcd. for C21H20BrN3OS: C:
57.02, H: 4.56, N: 9.50%. Found: C: 56.75, H: 4.98, N: 9.07%.
4.4.24. 5-(3-bromobenzyliden)thiazol[3,2-b][1,2,4]triazol-6
(5H)-one (24)
Yield: 79%, m.p. 191–193 C (dioxan), Rf = 0.53 (CHCl3), IR:
(cm1, Nujol): 1739 (C‚O), 1654 (C‚N). 1H NMR: (d ppm,
CDCl3, 300 MHz): 1.82–2.11 (m, 15H, adamantan), 7.39–7.45
(m, 1H, ArAH), 7.54 (d, J= 7,8 Hz, 1H, ArAH), 7.64 (d,
J= 8,1 Hz, 1H, ArAH), 7.75 (s, 1H, ArAH), 8.11 (s, 1H,
CH‚). Anal. Calcd.for C21H20BrN3OS: C: 57.02, H: 4.56,
N: 9.50%. Found: C: 57.35, H: 4.81, N: 9.13%.
4.4.25. 5-(4-bromobenzyliden)thiazol[3,2-b][1,2,4]triazol-6
(5H)-one (25)
Yield: 75%, m.p. 201–2033 C (ethanol), Rf = 0.41 (CHCl3),
IR:(cm1, Nujol): 1731 (C‚O), 1599 (C‚N). 1H NMR: (d
ppm, CDCl3, 300 MHz): 1.76–2.09 (m, 15H, adamantan),
7.58–7.69 (m, 2H, ArAH), 7.85 (dd, J1 = 7,8 Hz,
J2 = 1,8 Hz, 1H, ArAH), 8.25 (s, 1H, CH‚). Anal. Calcd.Please cite this article in press as: Tratrat, C. et al., Design, synthesis and biological
azol-6(5H)ones. Pharmacophore models for antifungal activity. Arabian Journal offor C21H20BrN3OS (MW 442): 57.02, H: 4.56, N: 9.50%.
Found: C: 57.10; H: 4.53, N: 9.56%.
4.5. Biological evaluation
4.5.1. Antibacterial activity
The following Gram-negative bacteria were used: E. coli
(ATCC 35210), P. aeruginosa (ATCC 27853), S. typhimurium
(ATCC 13311), E. cloacae (human isolate) and Gram-
positive bacteria: B. cereus (clinical isolate), M. flavus (ATCC
10240), L. monocytogenes (NCTC 7973) and S. aureus (ATCC
6538). The organisms were obtained from the Mycological
Laboratory, Department of Plant Physiology, Institute for
Biological Research ‘Sinisˇa Stankovic´’, Belgrade, Serbia. The
antibacterial assay was carried out by a microdilution method
(Hanel and Raether, 1988; Daouk et al., 1995) in order to
determine the antibacterial activity of compounds tested
against the human pathogenic bacteria. The bacterial suspen-
sions were adjusted with sterile saline to a concentration of
1.0 * 10
5 CFU/mL. The inocula were prepared daily and
stored at +4 C until use. Dilutions of the inocula were cul-
tured on solid medium to verify the absence of contamination
and to check the validity of the inoculum. All experiments were
performed in duplicate and repeated three times.
4.5.2. Microdilution test
The minimum inhibitory and bactericidal concentrations
(MICs and MBCs) were determined using 96-well microtitre
plates. The bacterial suspension was adjusted with sterile saline
to a concentration of 1.0 * 10
5 CFU/mL. Compounds to be
investigated were dissolved in 5% DMSO solution containing
0.1% Tween 80 (v/v) (1 mg/mL) and added in broth LB med-
ium (100 ll) with bacterial inoculum (1.0 * 10
4 CFU per well)
to achieve the wanted concentrations. The microplates were
incubated at Rotary shaker (160 rpm) for 24 h at 37 C. The
lowest concentrations without visible growth (at the binocular
microscope) were defined as concentrations that completely
inhibited bacterial growth (MICs). The MBCs were deter-
mined by serial sub-cultivation of 2 lL into microtitre plates
containing 100 lL of broth per well and further incubation
for 24 h. The lowest concentration with no visible growth
was defined as the MBC, indicating 99.5% killing of the orig-
inal inoculum. The optical density of each well was measured
at a wavelength of 655 nm by Microplate manager 4.0 (Bio-
Rad Laboratories) and compared with a blank and the positive
control. Streptomycin (Sigma P 7794) and Ampicillin (Pan-
farma, Belgrade, Serbia) were used as a positive control
(1 mg/mL in sterile physiological saline). Solution of 5%
DMSO was used as a negative control. All experiments were
performed in duplicate and repeated three times.
4.5.3. Antifungal activity
For the antifungal bioassays, eight fungi were used: A. niger
(ATCC 6275), A. ochraceus (ATCC 12066), A. fumigatus
(human isolate), A. versicolor (ATCC 11730), Penicillium
funiculosum (ATCC 36839), Penicillium ochrochloron (ATCC
9112), T. viride (IAM 5061) and C. albicans (human isolate).
The organisms were obtained from the Mycological Labora-
tory, Department of Plant Physiology, Institute for Biological
Research ‘Sinisˇa Stankovic´’, Belgrade, Serbia. The micromy-
cetes were maintained on malt agar and the cultures storedevaluation of new substituted 5-benzylideno-2-adamantylthiazol[3,2-b][1,2,4]tri-
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to investigate the antifungal activity of the compounds, a mod-
ified microdilution technique was used (Daouk et al., 1995;
Booth et al., 1971; Espinel-Ingroff, 2001). The fungal spores
were washed from the surface of agar plates with sterile
0.85% saline containing 0.1% Tween 80 (v/v). The spore sus-
pension was adjusted with sterile saline to a concentration of
approximately 1.0 * 10
5 in a final volume of 100 lL per well.
The inocula were stored at 4 C for further use. Dilutions of
the inocula were cultured on solid malt agar to verify the
absence of contamination and to check the validity of the
inoculum. Minimum inhibitory concentration (MIC) determi-
nations were performed by a serial dilution technique using
96-well microtiter plates. The compounds investigated were
dissolved in 5% DMSO solution containing 0.1% Tween 80
(v/v) (1 mg/mL) and added in broth Malt medium with inocu-
lum. The microplates were incubated at Rotary shaker
(160 rpm) for 72 h at 28 C. The lowest concentrations without
visible growth (at the binocular microscope) were defined as
MICs. The fungicidal concentrations (MFCs) were determined
by serial subcultivation of a 2 lL of tested compounds dis-
solved in medium and inoculated for 72 h, into microtiter
plates containing 100 lL of broth per well and further incuba-
tion 72 h at 28 C. The lowest concentration with no visible
growth was defined as MFC indicating 99.5% killing of the
original inoculum. Solution of 5% DMSO was used as a nega-
tive control, commercial fungicides, bifonazole (Srbolek,
Belgrade, Serbia) and ketoconazole (Zorkapharma, Sˇabac, Ser-
bia), were used as positive controls (1–3500 lg/mL). All exper-
iments were performed in duplicate and repeated three times.
4.6. Prediction of molecular properties
A next step was to proceed with the prediction of physically
significant descriptors and pharmaceutically relevant proper-
ties of the synthesized molecules. The QikProp (Maestro 9.8)
as a fast and accurate prediction software was used.
4.7. Multivariate data analysis
The aforementioned molecular properties in relation to their
antifungal and antibacterial activities constituted the dataset
that was further subjected to multivariate data analysis. In par-
ticular the SIMCA-P version 13.0 software (Umetrics, Umea˚,
Sweden) was utilized in order to implement Principal Compo-
nent Analysis (PCA).
A PCA model estimates the systematic variation in a data
matrix by a low dimensional model plane. The unsupervised
PCA pattern recognition method manages to extract the dom-
inant patterns in the data matrix in terms of a complementary
set of scores and loading plots, thus enabling a reduction of
dimensionality, a data exploration finding relationship
between objects, an estimation of the correlation structure of
the variables and investigation on the necessary components
(a linear combination of original features) to explain the
greater part of variance with a minimum loss of information
(Trygg et al., 2007).
The PCA model were UV scaled, extracted at a confidence
level of 95% and any observations at <5% were considered to
be outliers.
Loading plots were extracted to reveal the variables that
bear class discriminating power.Please cite this article in press as: Tratrat, C. et al., Design, synthesis and biological
azol-6(5H)ones. Pharmacophore models for antifungal activity. Arabian Journal ofThe quality of models was described by the goodness-of-fit
R2 (0 6 R2 6 1) and the predictive ability Q2 (0 6 Q2 6 1) val-
ues. The R2 explains the variation, thus constitutes a quantita-
tive measure of how well the data of the training set is
mathematically reproduced. The overall predictive ability of
the model is assessed by the cumulative Q2 representing the
fraction of the variation of Y that can be predicted by the
model and was extracted according to the internal cross valida-
tion default method of SIMCA-P software (Eriksson et al.,
2006).
In particular, all models demonstrated high statistical
values (R2 > 0.7 and Q2P 0.6), the difference between the
goodness-of-fit and the predictive ability remained always
lower than 0.2 (R2X(cum) – Q2(cum) < 0.2) and the
goodness-of-fit never equalled to one (R2X(cum)– 1). There-
fore, since the extracted models abide by these rules then their
robustness and predictive response are enhanced (Geladi et al.,
1989).
5. Material and methods for generation of pharmacophore
In order to perceive the important functional groups having
contributory role for fungal inhibition in A. fumigatus and
C. albicans common feature pharmacophore model (CFPM)
was developed using the synthesized compounds by HipHop
module in Discovery Studio (DS2.0) (Bhunia et al., 2015).
5.1. Selection of training set
In order to generate pharmacophore models six compounds 8,
16, 18, 19, 23 and 25 having promising inhibitory activity
(IC50 < 35 lM) toward Aspergillus fumigatus and C. albicans
were selected from the dataset of 25 molecules and 18 mole-
cules respectively and rest of the molecules were kept for
extending the pharmacophore model. As observed, the dataset
of synthesized molecules has variation in functionality regard-
ing the substituent at the phenyl ring, hence the criteria for
training set selection was based on the active molecules with
good diversity in functionality at this position.
5.2. Generation of pharmacophore model
The selected training set was utilized to develop CFPM for
both A. fumigatus and C. albicans for detection of important
chemical functionalities guiding activity. The HipHop module
in DS2.0 identifies common chemical feature pattern by over
laying molecules in the training set. The chemical functions
namely hydrogen bonding acceptor (HBA), ring aromatic
(RA), and hydrophobic aliphatic group (HAl), was selected
based on optimization procedure and the chemical features
present in the training set. Variations in the parameters related
to Maximum Omitted Features, Misses, and Complete Misses
were done due to the possibility of presence and absence of
chemical features in some compounds of the training set. In
this context, the ‘‘principal number” was set to 2 that ensure
that all chemical features in the compounds are considered
during generation of hypothesis space. The ‘‘maximum omit-
ting features” was set to 0 that force the mapping of chemical
features with the pharmacophore features. All the parameters
were kept default for the generation CFPM in both cases
(A. fumigatus and C. albicans). In hypothesis generation runevaluation of new substituted 5-benzylideno-2-adamantylthiazol[3,2-b][1,2,4]tri-
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basis of ranking score.
5.3. Conformation generation
The structures in the dataset were built using the 2D editor
ISIS draw 2.5 and imported to (DS2.0) window for the gener-
ation of 3D structures. The conformational search for each
molecule was next performed utilizing the best quality confor-
mational search option in DS2.0 keeping the energy threshold
constraint to 20 kcal mol1 above the global energy minimum.
To ensure proper conformation sampling, a maximum of 255
conformations in BEST mode were generated for each
structure.Appendix A. Supplementary material
Supplementary data associated with this article can be found,
in the online version, at http://dx.doi.org/10.1016/j.arabjc.
2016.06.007.References
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